Efficacy of Tildrakizumab Across Different Body Weights in Moderate-to-Severe Psoriasis Over 5 Years: Pooled Analyses from the reSURFACE Pivotal Studies

INTRODUCTION: Tildrakizumab (TIL), a monoclonal antibody that selectively targets interleukin-23p19, has been approved for the treatment of moderate-to-severe plaque psoriasis. According to the European Medicines Agency Summary of Product Characteristics, the recommended dose is 100 mg, but a 200 mg...

Descripción completa

Detalles Bibliográficos
Autores principales: Thaçi, Diamant, Gerdes, Sascha, Du Jardin, Kristian Gaarn, Perrot, Jean-Luc, Puig, Lluís
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515266/
https://www.ncbi.nlm.nih.gov/pubmed/36098877
http://dx.doi.org/10.1007/s13555-022-00793-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515266/
https://www.ncbi.nlm.nih.gov/pubmed/36098877
http://dx.doi.org/10.1007/s13555-022-00793-z

Ejemplares similares